Reviva Pharmaceuticals (RVPH) Competitors $0.98 -0.14 (-12.53%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RVPH vs. SCPH, SKYE, GBIO, RPTX, GALT, ELYM, CGEN, COYA, NVCT, and VXRTShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include scPharmaceuticals (SCPH), Skye Bioscience (SKYE), Generation Bio (GBIO), Repare Therapeutics (RPTX), Galectin Therapeutics (GALT), Eliem Therapeutics (ELYM), Compugen (CGEN), Coya Therapeutics (COYA), Nuvectis Pharma (NVCT), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. scPharmaceuticals Skye Bioscience Generation Bio Repare Therapeutics Galectin Therapeutics Eliem Therapeutics Compugen Coya Therapeutics Nuvectis Pharma Vaxart scPharmaceuticals (NASDAQ:SCPH) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Is SCPH or RVPH more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to scPharmaceuticals' net margin of -252.18%. Reviva Pharmaceuticals' return on equity of 0.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-252.18% -201.84% -70.42% Reviva Pharmaceuticals N/A N/A -280.50% Which has more risk & volatility, SCPH or RVPH? scPharmaceuticals has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Do insiders and institutionals hold more shares of SCPH or RVPH? 89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by company insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer SCPH or RVPH? scPharmaceuticals received 136 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.00% of users gave Reviva Pharmaceuticals an outperform vote while only 66.39% of users gave scPharmaceuticals an outperform vote. CompanyUnderperformOutperformscPharmaceuticalsOutperform Votes15866.39% Underperform Votes8033.61% Reviva PharmaceuticalsOutperform Votes2288.00% Underperform Votes312.00% Which has preferable earnings and valuation, SCPH or RVPH? Reviva Pharmaceuticals has lower revenue, but higher earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$24.05M8.47-$54.81M-$1.56-2.61Reviva PharmaceuticalsN/AN/A-$39.26M-$1.30-0.75 Does the media refer more to SCPH or RVPH? In the previous week, scPharmaceuticals and scPharmaceuticals both had 1 articles in the media. scPharmaceuticals' average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment scPharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer SCPH or RVPH? scPharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 342.26%. Reviva Pharmaceuticals has a consensus target price of $15.50, indicating a potential upside of 1,485.68%. Given Reviva Pharmaceuticals' higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Reviva Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryReviva Pharmaceuticals beats scPharmaceuticals on 10 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.45M$7.41B$5.50B$8.53BDividend YieldN/A7.96%5.11%4.13%P/E Ratio-0.7511.56124.2715.90Price / SalesN/A400.621,494.7597.45Price / CashN/A47.4239.7834.15Price / Book4.895.594.775.07Net Income-$39.26M$153.56M$119.06M$225.46M7 Day Performance-14.25%0.13%0.80%0.54%1 Month Performance-23.63%15.23%5.65%3.75%1 Year Performance-80.13%41.14%36.75%29.48% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.0289 of 5 stars$0.98-12.5%$15.50+1,485.7%-77.2%$37.45MN/A-0.755News CoverageGap UpHigh Trading VolumeSCPHscPharmaceuticals3.5044 of 5 stars$4.37+4.0%$18.00+311.9%-22.2%$157.56M$24.05M-2.8030SKYESkye Bioscience1.6381 of 5 stars$5.15+2.4%$18.67+262.5%+247.5%$156.25MN/A0.0011Gap UpGBIOGeneration Bio3.5194 of 5 stars$2.34+9.3%$7.50+220.5%+126.6%$156.17M$5.90M-0.98150Short Interest ↓Gap UpRPTXRepare Therapeutics3.0495 of 5 stars$3.66+5.2%$10.00+173.2%+2.6%$155.37M$51.13M-2.23180GALTGalectin Therapeutics1.7004 of 5 stars$2.49-0.8%$11.00+341.8%+24.4%$155.08MN/A-3.159Positive NewsELYMEliem TherapeuticsN/A$4.11-3.5%N/A+44.3%$152.03MN/A-7.7520CGENCompugen2.1965 of 5 stars$1.69-0.6%$4.00+136.7%+125.0%$150.82M$42.72M-16.9068Upcoming EarningsPositive NewsCOYACoya Therapeutics2.3564 of 5 stars$10.19+13.7%$16.67+63.6%+51.7%$148.96M$9.55M-13.966Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeNVCTNuvectis Pharma1.8853 of 5 stars$7.84-10.5%$21.00+167.9%-30.3%$146.22MN/A-6.088Gap UpHigh Trading VolumeVXRTVaxart1.9345 of 5 stars$0.84+1.2%$3.00+259.2%+19.2%$146.07M$7.38M-1.82109Upcoming EarningsNews Coverage Related Companies and Tools Related Companies SCPH Alternatives SKYE Alternatives GBIO Alternatives RPTX Alternatives GALT Alternatives ELYM Alternatives CGEN Alternatives COYA Alternatives NVCT Alternatives VXRT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RVPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
